Longtime partners in simplifying blood sample collection and testing, BD and Babson Diagnostics are now making their ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

After spending most of the year hunting for options to stay afloat, cash-strapped Portage Biotech appears to have found ...

Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...

Dexcom has launched a generative AI platform aimed at providing personalized lifestyle tips to the users of its ...

Biomea also drilled down into subgroups of patients with mild age-related diabetes and severe insulin-deficient diabetes, ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

The FDA is boosting a recall effort from Boston Scientific regarding batteries potentially underpowering a number of the ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped ...

Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a ...